{"id":"https://openalex.org/W4394598752","doi":"https://doi.org/10.1212/wnl.0000000000206715","title":"Novel Bispecific Degrader BHV-1300 Achieves Rapid, Robust, and Selective IgG Reduction in Preclinical Models Including Nonhuman Primates (S43.004)","display_name":"Novel Bispecific Degrader BHV-1300 Achieves Rapid, Robust, and Selective IgG Reduction in Preclinical Models Including Nonhuman Primates (S43.004)","publication_year":2024,"publication_date":"2024-04-09","ids":{"openalex":"https://openalex.org/W4394598752","doi":"https://doi.org/10.1212/wnl.0000000000206715"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.0000000000206715","doi":"https://doi.org/10.1212/wnl.0000000000206715","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.0000000000206715","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5045055908","display_name":"Anna Bunin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210093361","display_name":"Biohaven Pharmaceuticals (United States)","ror":"https://ror.org/00m2ky193","country_code":"US","type":"company","lineage":["https://openalex.org/I4210093361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anna Bunin","raw_affiliation_strings":["Biohaven Pharmaceuticals, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biohaven Pharmaceuticals, Inc","institution_ids":["https://openalex.org/I4210093361"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Seong Lee","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210093361","display_name":"Biohaven Pharmaceuticals (United States)","ror":"https://ror.org/00m2ky193","country_code":"US","type":"company","lineage":["https://openalex.org/I4210093361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Seong Lee","raw_affiliation_strings":["Biohaven Pharmaceuticals, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biohaven Pharmaceuticals, Inc","institution_ids":["https://openalex.org/I4210093361"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085429191","display_name":"Wes Kazmierski","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210093361","display_name":"Biohaven Pharmaceuticals (United States)","ror":"https://ror.org/00m2ky193","country_code":"US","type":"company","lineage":["https://openalex.org/I4210093361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wes Kazmierski","raw_affiliation_strings":["Biohaven Pharmaceuticals, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biohaven Pharmaceuticals, Inc","institution_ids":["https://openalex.org/I4210093361"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Kathleen McGrath","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210093361","display_name":"Biohaven Pharmaceuticals (United States)","ror":"https://ror.org/00m2ky193","country_code":"US","type":"company","lineage":["https://openalex.org/I4210093361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kathleen McGrath","raw_affiliation_strings":["Biohaven Pharmaceuticals, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biohaven Pharmaceuticals, Inc","institution_ids":["https://openalex.org/I4210093361"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103378384","display_name":"Ann Marie Rossi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210093361","display_name":"Biohaven Pharmaceuticals (United States)","ror":"https://ror.org/00m2ky193","country_code":"US","type":"company","lineage":["https://openalex.org/I4210093361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anne Marie Rossi","raw_affiliation_strings":["Biohaven Pharmaceuticals, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biohaven Pharmaceuticals, Inc","institution_ids":["https://openalex.org/I4210093361"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027193785","display_name":"Simone M. Nicholson","orcid":"https://orcid.org/0000-0003-0188-3936","observed_orcids":["https://orcid.org/0000-0003-0188-3936"]},"institutions":[{"id":"https://openalex.org/I4210093361","display_name":"Biohaven Pharmaceuticals (United States)","ror":"https://ror.org/00m2ky193","country_code":"US","type":"company","lineage":["https://openalex.org/I4210093361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Simone Nicholson","raw_affiliation_strings":["Biohaven Pharmaceuticals, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biohaven Pharmaceuticals, Inc","institution_ids":["https://openalex.org/I4210093361"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037635472","display_name":"Gene M. Dubowchik","orcid":"https://orcid.org/0000-0001-9666-5733","observed_orcids":["https://orcid.org/0000-0001-9666-5733"]},"institutions":[{"id":"https://openalex.org/I4210093361","display_name":"Biohaven Pharmaceuticals (United States)","ror":"https://ror.org/00m2ky193","country_code":"US","type":"company","lineage":["https://openalex.org/I4210093361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gene Dubowchik","raw_affiliation_strings":["Biohaven Pharmaceuticals, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biohaven Pharmaceuticals, Inc","institution_ids":["https://openalex.org/I4210093361"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031947369","display_name":"Elizabeth A. Dierks","orcid":"https://orcid.org/0000-0002-3654-4064","observed_orcids":["https://orcid.org/0000-0002-3654-4064"]},"institutions":[{"id":"https://openalex.org/I4210093361","display_name":"Biohaven Pharmaceuticals (United States)","ror":"https://ror.org/00m2ky193","country_code":"US","type":"company","lineage":["https://openalex.org/I4210093361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elizabeth Dierks","raw_affiliation_strings":["Biohaven Pharmaceuticals, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biohaven Pharmaceuticals, Inc","institution_ids":["https://openalex.org/I4210093361"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5095064951","display_name":"Neal Sharpe","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210093361","display_name":"Biohaven Pharmaceuticals (United States)","ror":"https://ror.org/00m2ky193","country_code":"US","type":"company","lineage":["https://openalex.org/I4210093361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Neal Sharpe","raw_affiliation_strings":["Biohaven Pharmaceuticals, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biohaven Pharmaceuticals, Inc","institution_ids":["https://openalex.org/I4210093361"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031735945","display_name":"David A. Pirman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210093361","display_name":"Biohaven Pharmaceuticals (United States)","ror":"https://ror.org/00m2ky193","country_code":"US","type":"company","lineage":["https://openalex.org/I4210093361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Pirman","raw_affiliation_strings":["Biohaven Pharmaceuticals, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biohaven Pharmaceuticals, Inc","institution_ids":["https://openalex.org/I4210093361"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001291631","display_name":"Bruce D. Car","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210093361","display_name":"Biohaven Pharmaceuticals (United States)","ror":"https://ror.org/00m2ky193","country_code":"US","type":"company","lineage":["https://openalex.org/I4210093361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bruce Car","raw_affiliation_strings":["Biohaven Pharmaceuticals, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biohaven Pharmaceuticals, Inc","institution_ids":["https://openalex.org/I4210093361"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011709863","display_name":"Irfan Qureshi","orcid":"https://orcid.org/0000-0002-0572-0993","observed_orcids":["https://orcid.org/0000-0002-0572-0993"]},"institutions":[{"id":"https://openalex.org/I4210093361","display_name":"Biohaven Pharmaceuticals (United States)","ror":"https://ror.org/00m2ky193","country_code":"US","type":"company","lineage":["https://openalex.org/I4210093361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Irfan Qureshi","raw_affiliation_strings":["Biohaven Pharmaceuticals, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biohaven Pharmaceuticals, Inc","institution_ids":["https://openalex.org/I4210093361"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069362203","display_name":"Vladimir Coric","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210093361","display_name":"Biohaven Pharmaceuticals (United States)","ror":"https://ror.org/00m2ky193","country_code":"US","type":"company","lineage":["https://openalex.org/I4210093361"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vladimir Coric","raw_affiliation_strings":["Biohaven Pharmaceuticals, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biohaven Pharmaceuticals, Inc","institution_ids":["https://openalex.org/I4210093361"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101539014","display_name":"David A. Spiegel","orcid":"https://orcid.org/0000-0002-1102-8012","observed_orcids":["https://orcid.org/0000-0002-1102-8012"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Spiegel","raw_affiliation_strings":["Yale University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale University","institution_ids":["https://openalex.org/I32971472"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.5094,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.57243375,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":96},"biblio":{"volume":"102","issue":"7_supplement_1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.8252000212669373,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.8252000212669373,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.13770000636577606,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11627","display_name":"Autoimmune Neurological Disorders and Treatments","score":0.006000000052154064,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antibody-degradation","display_name":"antibody degradation","score":0.48500001430511475},{"id":"https://openalex.org/keywords/nonhuman-primates","display_name":"non-human primates","score":0.828000009059906},{"id":"https://openalex.org/keywords/preclinical-pharmacology","display_name":"preclinical pharmacology","score":0.5149999856948853},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.5379999876022339}],"concepts":[{"id":"https://openalex.org/C111335779","wikidata":"https://www.wikidata.org/wiki/Q3454686","display_name":"Reduction (mathematics)","level":2,"score":0.56527179479599},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3432658314704895},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.32874804735183716},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.31492602825164795},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.12374594807624817},{"id":"https://openalex.org/C2524010","wikidata":"https://www.wikidata.org/wiki/Q8087","display_name":"Geometry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.0000000000206715","doi":"https://doi.org/10.1212/wnl.0000000000206715","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.0000000000206715","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9763000011444092,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4409226388","https://openalex.org/W4409227615","https://openalex.org/W7164209181","https://openalex.org/W4399483446","https://openalex.org/W2116547757","https://openalex.org/W4405045530","https://openalex.org/W4392353594","https://openalex.org/W4362541295","https://openalex.org/W3139037718","https://openalex.org/W2009028771"],"abstract_inverted_index":{"Objective:":[0],"Evaluate":[1],"IgG":[2,26,49,76,84,99,137,146,155,198,213,231],"reducing":[3,50,214],"effects":[4,109,254],"of":[5,10,19,110,120,145,159,174,222,230,250,253,274,319,340,377,396,433,452,464,495,509,541,555,567,600,612,636,645,648,661,670,673,701,714,725,734,737,772,791,810,843],"BHV-1300.":[6,175],"Background:":[7],"Approximately":[8],"3\u201310%":[9],"the":[11,105,271,462,565,610,634,646,659,671,723,735,770,789,808],"population":[12],"is":[13,72,91],"affected":[14],"by":[15],"autoimmune":[16,287],"diseases,":[17],"many":[18],"which":[20],"are":[21,34],"associated":[22],"with":[23,61,151,237,243,266,279],"pathogenic":[24],"autoantibodies.":[25],"targeting":[27],"approaches":[28],"(Fc":[29],"receptor":[30],"antagonists,":[31],"plasmapheresis,":[32],"IVIG)":[33],"now":[35],"approved":[36],"or":[37,87,177,258,294,360,416,620,643,668,732,757,863],"used":[38],"in":[39,104,127,136,154,162,186,200,326,347,383,403,439,461,481,515,522,564,581,587,609,633,658,682,688,722,745,769,788,807,824,831,838],"various":[40],"neurological":[41],"disorders":[42,288],"including":[43,289],"myasthenia":[44],"gravis":[45],"(MG).":[46],"Importantly,":[47],"available":[48],"therapeutics":[51],"have":[52,65],"suboptimal":[53],"pharmacology":[54],"and":[55,64,68,81,130,164,196,202,239,264,286],"pharmacodynamic":[56],"effects,":[57],"cannot":[58],"be":[59,235],"co-administered":[60,236],"monoclonal":[62],"antibodies,":[63],"mechanism-based":[66],"safety":[67],"tolerability":[69],"issues.":[70],"BHV-1300":[71,90,111,191,216,269],"a":[73,92,275,358,414,572,617,755,777,796,815,861],"first-in-class":[74],"extracellular":[75],"degrader":[77],"engineered":[78],"to":[79,124,207,226,234,306,363,419,528,760,866],"rapidly":[80],"efficiently":[82],"deplete":[83],"after":[85,118,156,171],"intravenous":[86],"subcutaneous":[88],"injection.":[89],"bispecific":[93],"molecule":[94],"that":[95],"specifically":[96],"targets":[97],"intravascular":[98],"for":[100,210,261,284,314,335,372,391,428,447,466,472,490,504,536,550,569,574,595,614,625,638,650,663,675,696,709,727,739,774,779,793,798,812,817],"rapid":[101,143],"lysosomal":[102],"degradation":[103],"liver.":[106],"Design/Methods:":[107],"Pharmacodynamic":[108],"on":[112,255,616],"circulating":[113],"immunoglobulin":[114],"isotypes":[115],"were":[116,169,179],"evaluated":[117],"administration":[119],"single/multiple":[121],"doses":[122,158,173],"up":[123],"500":[125],"mg/kg":[126],"cynomolgus":[128],"macaques":[129],"rabbits.":[131,165,203],"Results:":[132],"Deep,":[133],"dose-dependent":[134],"reductions":[135,153,168,199],"concentrations":[138],"occurred.":[139],"Concentration":[140],"profiles":[141],"showed":[142],"onset":[144],"reduction":[147],"within":[148],"6":[149],"hours,":[150],"deep":[152],"single":[157],"approximately":[160],"75\u201380%":[161],"monkeys":[163,201],"Deeper,":[166],"92%":[167],"observed":[170],"multiple":[172],"IgA":[176],"IgM":[178],"not":[180],"impacted.":[181],"No":[182],"significant":[183],"changes":[184],"occurred":[185],"clinical":[187],"chemistry":[188],"parameters.":[189],"Conclusions:":[190],"demonstrated":[192],"rapid,":[193],"robust,":[194],"safe,":[195],"selective":[197],"This":[204],"compares":[205],"favorably":[206],"published":[208],"data":[209],"FcRn":[211],"inhibitor":[212],"therapies;":[215],"has":[217,304,310,324,331,345,352,368,381,387,401,408,424,437,443,457,479,486,500,513,520,526,532,546,560,579,585,591,605,629,654,680,686,692,705,718,743,749,765,784,803,822,829,836,846,855],"important":[218],"differentiating":[219],"properties:":[220],"speed":[221],"onset,":[223],"shortened":[224],"time":[225],"maximal":[227],"effect,":[228],"depth":[229],"lowering,":[232],"ability":[233],"biologics":[238],"target-related":[240],"safety.":[241],"Coupled":[242],"other":[244],"potential":[245,260],"mechanistic":[246],"advantages":[247],"(brief":[248],"period":[249],"exposure;":[251],"lack":[252],"albumin,":[256],"cholesterol,":[257],"triglycerides;":[259],"reduced":[262],"immunosuppression;":[263],"compatibility":[265],"Fc-containing":[267],"biologics),":[268],"represents":[270],"first":[272],"member":[273,644,669,733],"new":[276],"drug":[277],"class":[278],"potentially":[280],"significantly":[281],"improved":[282],"benefit-risk":[283],"neuroinflammatory":[285],"acute":[290],"manifestations":[291],"(MG":[292],"crises/flares)":[293],"chronic":[295],"disease":[296],"(MG,":[297],"rheumatoid":[298],"arthritis,":[299],"etc).":[300],"Disclosure:":[301],"Dr.":[302,329,343,350,422,435,484,498,511,518,524,530,544,558,577,583,589,603,627,652,678,684,690],"Bunin":[303],"nothing":[305,527],"disclose.":[307,529],"Mr.":[308,322],"Lee":[309,323],"received":[311,332,353,369,388,409,425,444,458,487,501,533,547,561,592,606,630,655,693,706,719,750,766,785,804,847,856],"personal":[312,333,370,389,426,445,459,488,502,534,548,562,593,607,631,656,694,707,720,767,786,805],"compensation":[313,334,371,390,427,446,460,489,503,535,549,563,594,608,632,657,695,708,721,768,787,806],"serving":[315,336,373,392,429,448,467,491,505,537,551,570,596,615,639,664,697,710,728,775,794,813],"as":[316,337,374,393,430,449,468,492,506,538,552,571,597,640,665,698,711,729,776,795,814],"an":[317,338,375,394,431,450,469,493,507,539,553,598,641,666,699,712,730],"employee":[318,339,376,395,432,451,494,508,540,554,599,700,713],"Biohaven":[320,327,341,348,397,404,453,482,496,516,542,601,780,825,851],"Pharmaceuticals.":[321,328,342,349,398,405,454,483,497,517,543,557,602,677,781,826,852],"stock":[325,346,382,402,438,480,514,521,580,586,681,687,744,823,830,837],"Kazmierski":[330,344,351],"intellectual":[354,410,751,857],"property":[355,411,752,858],"interests":[356,412,753,859],"from":[357,413,754,850,860],"discovery":[359,415,756,862],"technology":[361,417,758,864],"relating":[362,418,759,865],"health":[364,420,761,867],"care.":[365,421,762,868],"Ms.":[366,379,385,399,406],"McGrath":[367,380],"Biohaven.":[378,384,434,440,582,651,702,715,746],"ROSSI":[386,400,407],"Nicholson":[423,436],"Gene":[441,455,477],"Dubowchik":[442,456,478],"range":[463,566,611,635,660,724,771,790,809],"$100,000-$499,999":[465,792,811],"Expert":[470],"Witness":[471],"Morrison":[473],"&":[474],"Foerster":[475],"LLP.":[476],"Dierks":[485,499,512,519],"BMS.":[510,523],"Sharpe":[525],"Pirman":[531,545,559,578,584],"Agios":[556,676],"$5,000-$9,999":[568],"Consultant":[573,778,797,816],"Scaffold":[575],"Therapeutics.":[576,819,840],"Agios.":[588,689],"Car":[590,604,628,653,679,685],"$10,000-$49,999":[613],"Scientific":[618],"Advisory":[619],"Data":[621],"Safety":[622],"Monitoring":[623],"board":[624],"PathAI.":[626],"$500,000-$999,999":[637],"officer":[642,667,731],"Board":[647,672,736],"Directors":[649,674,738],"$1,000,000+":[662,726,773],"biohaven.":[683],"Qureshi":[691],"Vladimir":[703,716,741,747],"Coric":[704,717,742,748],"Bioahven.":[740],"Prof.":[763,782,801,820,827,834,844,853],"Spiegel":[764,783,802,821,828,835,845,854],"Magnet":[799,832],"Biomedicine.":[800],"Kymera":[818,839],"biomedicine.":[833],"The":[841],"institution":[842],"research":[848],"support":[849]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2024-04-10T00:00:00"}